QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
Most-Upgraded Stocks  
NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$321.32
+3.74 (+1.18%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$316.95
▼
$324.75
50-Day Range
$287.89
▼
$321.48
52-Week Range
$204.11
▼
$324.75
Volume
1.14 million shs
Average Volume
1.59 million shs
Market Capitalization
$82.48 billion
P/E Ratio
25.34
Dividend Yield
N/A
Price Target
$305.33

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
5.0% Downside
$305.33 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.71mentions of Vertex Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.13 M Sold Last Quarter
Proj. Earnings Growth
5.36%
From $13.05 to $13.75 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

432nd out of 1,022 stocks

Pharmaceutical Preparations Industry

187th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

November 10, 2022 | marketbeat.com
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (VRTX)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
December 8, 2022 | nasdaq.com
Vertex, Entrada To Develop Endosomal Escape Vehicle Therapeutics For Myotonic Dystrophy Type 1
December 8, 2022 | finance.yahoo.com
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
December 8, 2022 | finance.yahoo.com
Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy
December 8, 2022 | finance.yahoo.com
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
December 8, 2022 | finance.yahoo.com
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Been Rising: Are Strong Financials Guiding The Market?
December 6, 2022 | finance.yahoo.com
2 Sector ETFs Hovering Around a 52-Week High
December 5, 2022 | finance.yahoo.com
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
December 4, 2022 | finance.yahoo.com
Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 124%
December 4, 2022 | finance.yahoo.com
Is This Biotech Stock a Buy Following a Landmark Approval?
December 1, 2022 | finance.yahoo.com
3 Growth Stocks That Are Too Cheap to Ignore
November 30, 2022 | finance.yahoo.com
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 37% Discount?
November 30, 2022 | stocknews.com
3 Biotech Stocks to Buy Before December and 1 to Sell
November 29, 2022 | seekingalpha.com
Vertex Pharmaceuticals: Growth Outside Of Cystic Fibrosis Critical For Additional Value Creation
November 26, 2022 | finance.yahoo.com
Are Robust Financials Driving The Recent Rally In Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock?
November 24, 2022 | msn.com
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,900 Today
November 23, 2022 | finance.yahoo.com
GSK to Withdraw Blenrep From U.S. Market on FDA Request
November 22, 2022 | finance.yahoo.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 36% Below Their Intrinsic Value Estimate
November 21, 2022 | finance.yahoo.com
Why Vertex Pharmaceuticals (VRTX) is a Top Value Stock for the Long-Term
November 18, 2022 | finance.yahoo.com
Dow Jones Futures: 7 Investing Rules For A Tricky Market Rally; Tesla Skids To Bear Market Lows
November 18, 2022 | finance.yahoo.com
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 37% Undervalued
November 18, 2022 | finance.yahoo.com
3 Top Growth Stocks to Buy Sooner Rather Than Later
November 17, 2022 | markets.businessinsider.com
6 Analysts Have This to Say About Vertex Pharmaceuticals
November 17, 2022 | finance.yahoo.com
VRTX or TECH: Which Is the Better Value Stock Right Now?
November 16, 2022 | seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Jefferies London Healthcare Conference (Transcript)
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
10/27/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
1/25/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
CIK
875320
Web
www.vrtx.com
Phone
(617) 341-6100
Fax
617-576-2109
Employees
3,900
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$305.33
High Stock Price Forecast
$365.00
Low Stock Price Forecast
$222.00
Forecasted Upside/Downside
-5.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$12.68
Trailing P/E Ratio
25.34
Forward P/E Ratio
24.62
P/E Growth
1.75
Net Income
$2.34 billion
Net Margins
37.62%
Pretax Margin
46.28%
Return on Equity
29.65%
Return on Assets
22.73%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
4.70
Quick Ratio
4.55

Sales & Book Value

Annual Sales
$7.57 billion
Price / Sales
10.89
Cash Flow
$13.02 per share
Price / Cash Flow
24.68
Book Value
$39.72 per share
Price / Book
8.09

Miscellaneous

Outstanding Shares
256,691,000
Free Float
255,664,000
Market Cap
$82.48 billion
Optionable
Optionable
Beta
0.43

Social Links


Key Executives

  • Dr. Jeffrey Marc Leiden M.D. (Age 66)
    Ph.D., Exec. Chairman
    Comp: $281.98k
  • Dr. Reshma Kewalramani FASNDr. Reshma Kewalramani FASN (Age 49)
    M.D., CEO, Pres & Director
    Comp: $4.27M
  • Mr. Charles F. Wagner Jr.Mr. Charles F. Wagner Jr. (Age 54)
    Exec. VP & CFO
    Comp: $1.85M
  • Mr. Stuart A. Arbuckle B.Sc.Mr. Stuart A. Arbuckle B.Sc. (Age 56)
    Exec. VP & COO
    Comp: $2.56M
  • Dr. Ourania Tatsis Ph.D. (Age 51)
    Exec. VP and Chief Regulatory & Quality Officer
    Comp: $1.33M
  • Ms. Kristen C. AmbroseMs. Kristen C. Ambrose (Age 45)
    Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
  • Dr. David M. Altshuler M.D. (Age 57)
    Ph.D., Exec. VP of Global Research & Chief Scientific Officer
  • Mr. Mike Tirozzi
    SVP and Chief Information & Data Officer
  • Susie Lisa
    Sr. VP of Investor Relations
  • Mr. Damian W. Wilmot Esq. (Age 46)
    Sr. VP, Chief Risk and Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2023?

17 brokerages have issued 12 month price objectives for Vertex Pharmaceuticals' stock. Their VRTX share price forecasts range from $222.00 to $365.00. On average, they predict the company's share price to reach $305.33 in the next year. This suggests that the stock has a possible downside of 5.1%.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2022?

Vertex Pharmaceuticals' stock was trading at $219.60 at the start of the year. Since then, VRTX shares have increased by 46.5% and is now trading at $321.75.
View the best growth stocks for 2022 here.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our VRTX earnings forecast.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Thursday, October, 27th. The pharmaceutical company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.31. The pharmaceutical company earned $2.33 billion during the quarter, compared to the consensus estimate of $2.23 billion. Vertex Pharmaceuticals had a net margin of 37.62% and a trailing twelve-month return on equity of 29.65%.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.80 billion-$8.90 billion, compared to the consensus revenue estimate of $8.77 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.83%), Vanguard Group Inc. (8.23%), State Street Corp (4.79%), Alliancebernstein L.P. (3.56%), Price T Rowe Associates Inc. MD (2.01%) and Jennison Associates LLC (1.85%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $321.75.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $82.59 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.68 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 12/8/2022 by MarketBeat.com Staff